Autolus Therapeutics Stock Today
| AUTL Stock | USD 1.68 0.26 13.40% |
PerformanceVery Weak
| Odds Of DistressBelow Average
|
Autolus Therapeutics is selling for 1.68 as of the 20th of March 2025. This is a 13.4 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.68. Autolus Therapeutics has about a 37 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of December 2024 and ending today, the 20th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of June 2018 | Category Healthcare | Classification Health Care |
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. Autolus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 266.12 M outstanding shares of which 9.49 M shares are presently shorted by private and institutional investors with about 7.39 trading days to cover. More on Autolus Therapeutics
Moving together with Autolus Stock
Moving against Autolus Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Autolus Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsAutolus Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Autolus Therapeutics' financial leverage. It provides some insight into what part of Autolus Therapeutics' total assets is financed by creditors.
| |||||
Autolus Therapeutics (AUTL) is traded on NASDAQ Exchange in USA. It is located in The Mediaworks, London, United Kingdom, W12 7FP and employs 463 people. Autolus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 516.28 M. Autolus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 266.12 M outstanding shares of which 9.49 M shares are presently shorted by private and institutional investors with about 7.39 trading days to cover.
Autolus Therapeutics currently holds about 216.44 M in cash with (145.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.38, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Autolus Therapeutics Probability Of Bankruptcy
Ownership AllocationAutolus Therapeutics holds a total of 266.12 Million outstanding shares. The majority of Autolus Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Autolus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Autolus Therapeutics. Please pay attention to any change in the institutional holdings of Autolus Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that nearly eleven million one hundred seventy-seven thousand one hundred twenty-four invesors are currently shorting Autolus Therapeutics expressing very little confidence in its future performance.
Check Autolus Ownership Details
Autolus Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Laurion Capital Management Lp | 2024-12-31 | 3.2 M | |
| Great Point Partners Llc | 2024-12-31 | 3 M | |
| T. Rowe Price Associates, Inc. | 2024-12-31 | 2.9 M | |
| Schroder Investment Management Group | 2024-12-31 | 2.9 M | |
| Axa Sa | 2024-12-31 | 1.8 M | |
| Bank Of New York Mellon Corp | 2024-12-31 | 1.7 M | |
| Millennium Management Llc | 2024-12-31 | 1.7 M | |
| Perpetual Ltd | 2024-12-31 | 1.3 M | |
| Jpmorgan Chase & Co | 2024-12-31 | 1.1 M | |
| Wellington Management Company Llp | 2024-12-31 | 25.3 M | |
| Blackstone Inc | 2024-12-31 | 20.5 M |
Autolus Therapeutics Historical Income Statement
Autolus Stock Against Markets
Autolus Therapeutics Corporate Management
| Olivia Manser | Director Relations | Profile | |
| David Brochu | Senior Officer | Profile | |
| Chris Williams | Senior Development | Profile | |
| Robert Dolski | Chief Officer | Profile | |
| Lucinda Crabtree | Chief Officer | Profile | |
| Alexander Swan | Senior Officer | Profile |
Already Invested in Autolus Therapeutics?
The danger of trading Autolus Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Autolus Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Autolus Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Autolus Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Autolus Therapeutics is a strong investment it is important to analyze Autolus Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Autolus Therapeutics' future performance. For an informed investment choice regarding Autolus Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Autolus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Autolus Stock please use our How to buy in Autolus Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Autolus Therapeutics. If investors know Autolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Autolus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.22) | Revenue Per Share | Quarterly Revenue Growth 6.81 | Return On Assets | Return On Equity |
The market value of Autolus Therapeutics is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Autolus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.